Takeda, Joint Venture End Collaboration On U.S. Cancer Drug
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical said it and CanBas, a joint venture of two Japanese medical schools, have ended their U.S. development of a lung cancer drug